| 发明名称 | Liquid pharmaceutical formulations of palonosetron | ||
| 摘要 | The present invention relates to shelf-stable liquid formulations of palonosetron for reducing chemotherapy and radiotherapy induced emesis with palonosetron. The formulations are particularly useful in the preparation of intravenous and oral liquid medicaments. | ||
| 申请公布号 | US9173942(B2) | 申请公布日期 | 2015.11.03 |
| 申请号 | US201313901830 | 申请日期 | 2013.05.24 |
| 申请人 | HELSINN HEALTHCARE SA;Roche Palo Alto LLC | 发明人 | Calderari Giorgio;Bonadeo Daniele;Cannella Roberta;Macciocchi Alberto;Miksztal Andrew;Malefyt Thomas;Lee Kathleen M |
| 分类号 | A01N43/52;A61K47/26;A61K47/18;A61K47/12;A61K47/00;A61K31/473;A61K47/02;A61K9/00;B65B7/16;B65B55/02 | 主分类号 | A01N43/52 |
| 代理机构 | Troutman Sanders LLP | 代理人 | Troutman Sanders LLP |
| 主权项 | 1. A formulation comprising a pharmaceutical sterile aqueous intravenous solution, wherein said pharmaceutical sterile aqueous intravenous solution comprises: palonosetron hydrochloride or another pharmaceutically acceptable salt of palonosetron at a concentration of 0.05 mg/mL based on the weight of the palonosetron free base; and from 10 mg/mL to 80 mg/mL mannitol; wherein the pharmaceutical sterile aqueous intravenous solution has a pH of 4.0 to 6.0. | ||
| 地址 | Pambio-Noranco CH | ||